126 related articles for article (PubMed ID: 22457313)
1. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.
Nalda-Molina R; Dokoumetzidis A; Charkoftaki G; Dimaraki E; Margetis K; Archontaki H; Markantonis S; Boutos N; Sakas D; Vryonis E; Skoutelis A; Valsami G
J Antimicrob Chemother; 2012 Jul; 67(7):1722-9. PubMed ID: 22457313
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia.
Harada M; Inui N; Suda T; Nakamura Y; Wajima T; Matsuo Y; Chida K
Int J Antimicrob Agents; 2013 Aug; 42(2):149-54. PubMed ID: 23684002
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH
Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL
Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
[TBL] [Abstract][Full Text] [Related]
5. Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics.
Viaggi B; Paolo AD; Danesi R; Polillo M; Ciofi L; Del Tacca M; Malacarne P
Scand J Infect Dis; 2011 Sep; 43(9):721-7. PubMed ID: 21585240
[TBL] [Abstract][Full Text] [Related]
6. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
[TBL] [Abstract][Full Text] [Related]
7. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Roberts JA; Lipman J
Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients.
Ikawa K; Morikawa N; Urakawa N; Ikeda K; Ohge H; Sueda T
J Antimicrob Chemother; 2007 Dec; 60(6):1395-7. PubMed ID: 17884833
[TBL] [Abstract][Full Text] [Related]
9. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.
Luque S; Grau S; Alvarez-Lerma F; Ferrández O; Campillo N; Horcajada JP; Basas M; Lipman J; Roberts JA
Int J Antimicrob Agents; 2014 Nov; 44(5):409-15. PubMed ID: 25216547
[TBL] [Abstract][Full Text] [Related]
10. Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis.
Tanoue K; Nishi K; Kadowaki D; Hirata S
Ther Apher Dial; 2011 Jun; 15(3):327-33. PubMed ID: 21624085
[TBL] [Abstract][Full Text] [Related]
11. Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients.
Yamada Y; Ikawa K; Nakamura K; Mitsui K; Narushima M; Hibi H; Ikeda K; Morikawa N; Honda N
Int J Antimicrob Agents; 2010 May; 35(5):504-6. PubMed ID: 20188521
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
Cirillo I; Vaccaro N; Redman R; Black PL; Kearns GL
J Clin Pharmacol; 2012 Nov; 52(11):1645-53. PubMed ID: 22174436
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.
Cirillo I; Vaccaro N; Turner K; Solanki B; Natarajan J; Redman R
J Clin Pharmacol; 2009 Jul; 49(7):798-806. PubMed ID: 19553404
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment.
Matsuo Y; Ishibashi T; Kubota R; Wajima T
J Infect Chemother; 2015 Feb; 21(2):123-9. PubMed ID: 25487084
[TBL] [Abstract][Full Text] [Related]
16. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime.
Avedissian SN; Pais G; Joshi MD; Rhodes NJ; Scheetz MH
mSphere; 2019 Jan; 4(1):. PubMed ID: 30700511
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.
Kanellakopoulou K; Pagoulatou A; Stroumpoulis K; Vafiadou M; Kranidioti H; Giamarellou H; Giamarellos-Bourboulis EJ
J Antimicrob Chemother; 2008 Jun; 61(6):1328-31. PubMed ID: 18353805
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
Chung EK; Fleming MR; Cheatham SC; Kays MB
Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and brain penetration of carbapenems in mice.
Matsumoto K; Kurihara Y; Kuroda Y; Hori S; Kizu J
J Infect Chemother; 2016 May; 22(5):346-9. PubMed ID: 26809218
[TBL] [Abstract][Full Text] [Related]
20. Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation.
Nakamura K; Ikawa K; Yamada Y; Arakawa M; Zennami K; Nishikawa G; Ikeda K; Morikawa N; Honda N
J Chemother; 2012 Feb; 24(1):32-7. PubMed ID: 22546722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
